Merus N.V.
MRUSDelisted Dec 30, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001651311
Merus N.V. was delisted on Dec 30, 2025; its insiders filed their last Form 4 on Dec 30, 2025; 268 institutions reported holding it in 13F filings for Q3 2025, worth $6.70B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 268
- Q3 2025, +67 vs. previous quarter
- 13F value
- $6.70B
- Reported value at the end of Q3 2025
- Superinvestors holding
- 1
- At the end of Q3 2025
Superinvestors holding MRUS, Q3 2025
1 superinvestor reports holding Merus N.V. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Merus N.V. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 (view filing) | Dec 26-29 | 4 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +1.06M | $97.00 | +$102.4M | +1.4%73.9M after | 2 lots |
| Dec 30, 2025 (view filing) | Dec 29 | 1 day | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | −75.9M | $97.00 | −$7.36B | −100.0%0 after | |
| Dec 29, 2025 (view filing) | Dec 22-26 | 7 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +815.4K | $97.00 | +$79.1M | +1.1%72.8M after | 4 lots |
| Dec 22, 2025 (view filing) | Dec 18-19 | 4 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +278.4K | $97.00 | +$27.0M | +0.4%72.0M after | 2 lots |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +271.5K | $97.00 | +$26.3M | +0.4%71.7M after | 2 lots |
| Dec 10, 2025 (view filing) | Nov 26 | 14 daysLate | Shuman HarryVP Controller, PAO | SSale | −1.70K | $96.10 | −$163.4K | −13.4%11.0K after | |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Shuman HarryVP Controller, PAO | SSale | −8.30K | $95.92 | −$796.1K | −43.0%11.0K after | |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Silverman Peter B.COO & GC | SSale | −25.0K | $60.00 | −$1.50M | −100.0%0 after | 10b5-1 |
| Jul 11, 2025 (view filing) | Jul 9-10 | 2 days | Silverman Peter B.COO & GC | SSale | −23.5K | $55.00 | −$1.29M | −100.0%0 after | 2 lots10b5-1 |
| Jun 24, 2025 (view filing) | Jun 20 | 4 days | Silverman Peter B.COO & GC | SSale | −34.0K | $52.76 | −$1.79M | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q3 2025
The largest institutional positions in Merus N.V. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 4,373,770 | $411.8M | 12.18% | +91,816+2.1% | Added |
| Avoro Capital Advisors LLC | 3,542,500 | $333.5M | 4.31% | +386,945+12.3% | Added |
| Commodore Capital LP | 3,525,000 | $331.9M | 16.20% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 3,046,916 | $286.9M | 4.40% | −337,712−10.0% | Reduced |
| HBK Investments L P | 2,850,000 | $268.3M | 3.95% | +2,850,000 | New |
| FMR LLC | 2,810,935 | $264.6M | 0.01% | −4,679,442−62.5% | Reduced |
| BlackRock, Inc. | 2,172,015 | $204.5M | 0.00% | +1,121,073+106.7% | Added |
| Westfield Capital Management Co LP | 2,132,489 | $200.8M | 0.84% | +90,101+4.4% | Added |
| RTW Investments, LP | 2,025,277 | $190.7M | 2.35% | −1,975,276−49.4% | Reduced |
| Woodline Partners LP | 1,674,167 | $157.6M | 0.74% | +131,267+8.5% | Added |